GTP

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
Tuesday, April 9, 2024
Mutation, Growth, NSCLC, Colorectal cancer, RAS, Patient, Research, PDAC, Lung cancer, GTP, AACR, Clinical trial, Cancer, CRC, G13, G12, Pharmaceutical industry

This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC).
  • RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers.
  • The paper describes the discovery of RMC-6236, an oral, multi-selective inhibitor of the active GTP-bound (ON) state of both mutant and wild-type RAS.

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
Monday, April 8, 2024
NSCLC, Colorectal cancer, CYPA, RAS, Patient, Research, PDAC, Lung cancer, Protein, Trial of the century, GTP, Cancer, CRC, Pharmacology, Ras GTPase, Drug resistance, Pharmaceutical industry

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of two peer-reviewed research papers in Nature. The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants.
  • The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC).

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.

Retrieved on: 
Thursday, April 4, 2024
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Gene editing, Therapeutic Goods Administration, University, Patient, Gene, MD, Quality of life, IND, GTP, Liver, MHRA, OTC, Pediatrics, Safety, Pharmacokinetics, TGA, Food, Medication, Pharmaceutical industry

ECUR-506 will be evaluated in the OTC-HOPE study in newborn males with genetically confirmed neonatal onset OTC deficiency.

Key Points: 
  • ECUR-506 will be evaluated in the OTC-HOPE study in newborn males with genetically confirmed neonatal onset OTC deficiency.
  • The OTC-HOPE study was previously cleared to begin in the United Kingdom by the Medicines & Healthcare Products Regulatory Agency (MHRA) and Australia by the Therapeutic Goods Administration (TGA).
  • “There is a significant need for clinical research and treatment options for newborns with severe, neonatal onset OTC deficiency,” said Gabriel M. Cohn, MD, Chief Medical Officer of iECURE.
  • “We hope that treatment with this investigational therapeutic will show promise for clinically meaningful improvements for infants with neonatal onset OTC deficiency and their families.”

Aviz Upgrades Packet Broker Lineup with Advanced Mobile 5G Service Nodes: Broadens AI-Driven Network Copilot's Use Cases

Retrieved on: 
Thursday, March 21, 2024
Technology, Networks, 5G, Telecommunications, OPB, Synthetic media, GPRS, N4, Aviz, LTE, AI, S11, Speed, IMEI, GTP, N11, IDS, IMSI, Mobile phone

Global and regional telecom carriers seek to deliver more personalized 5G services for better user experiences and to introduce rich new mobile services.

Key Points: 
  • Global and regional telecom carriers seek to deliver more personalized 5G services for better user experiences and to introduce rich new mobile services.
  • That’s why Aviz is integrating advanced service nodes into its comprehensive network visibility portfolio, while setting a new benchmark for telco 5G deployment support.
  • Avizy allows for the most flexible deployments alongside the Aviz Open Packet Broker (OPB) or with any third-party packet broker system, emphasizing its adaptability and open design.
  • To learn more about Aviz commitment to Networking 3.0 through service nodes, GenAI Network Copilot and telco-focused 5G network visibility, please visit the following resources:

GreyOrange Demonstrates Results-Driven Robotics During MODEX

Retrieved on: 
Tuesday, March 5, 2024
Robotics, CRN, Congress Center, Entrepreneurship, GTP, Ecosystem, Automation, VR, Human, AMR, Warehouse

ATLANTA, March 05, 2024 (GLOBE NEWSWIRE) -- GreyOrange Inc ., a leader in AI-driven fulfillment automation, is demonstrating what tailored results-driven robotics within fulfillment environments look like during MODEX 2024 in Atlanta at the Georgia World Congress Center.

Key Points: 
  • ATLANTA, March 05, 2024 (GLOBE NEWSWIRE) -- GreyOrange Inc ., a leader in AI-driven fulfillment automation, is demonstrating what tailored results-driven robotics within fulfillment environments look like during MODEX 2024 in Atlanta at the Georgia World Congress Center.
  • “GreyOrange continues to set standards and advance the industry by partnering with credible hardware vendors as part of our Certified Ranger Network, including Hai Robotics, Quicktron, Youibot, Wellwit Robotics, Mushiny, Tompkins Robotics, and Cypher Robotics,” said Akash Gupta, Co-Founder and CEO, GreyOrange.
  • MODEX attendees can visit Booth #C5692 to engage with GreyOrange leaders during live demonstrations, including several Certified Ranger Network bots that will demonstrate how GreyMatter is providing “results-driven robotics" - also GreyOrange’s MODEX theme - within automated warehouses.
  • Attendees from across the globe can register for the conference and schedule to meet with a GreyOrange subject matter expert to witness multiagent orchestration firsthand as AMRs from GreyOrange, HAI Robotics, Quicktron, YOUIBOT, Wellwit Robotics, and Mushiny work together for seamless fulfillment.

Porsche 963 of Porsche Penske Motorsport victorious after gripping 24 Hours of Daytona

Retrieved on: 
Monday, January 29, 2024
Proton, Daytona Beach, Florida, Candy, Porsche in motorsport, GTP, Mercedes-AMG, BMW M4, Proton Competition, Alessio Picariello, WeatherTech, Motorsport, Human, Emotion, GTD, IMSA, Moon, Competition, Team Penske, Professional corporation, JDC, Cadillac, Michelin, Acura, Fever, GT3, Ferrari, Mobil, Automotive industry

7 Porsche 963 fielded by the Porsche Penske Motorsport factory team has won the 24 Hours of Daytona.

Key Points: 
  • 7 Porsche 963 fielded by the Porsche Penske Motorsport factory team has won the 24 Hours of Daytona.
  • “The entire Porsche Penske Motorsport works team and everyone at the development center in Weissach [Germany] have worked extremely hard to lay the foundations for this success.
  • Four Porsche 963, two from Porsche Penske Motorsport and two from our strong customer teams, made it through without any major technical problems – that’s quite a feat in itself.
  • Daytona was definitely worth the trip for us.”
    “An amazing day for the entire Porsche Penske Motorsport organization,” said Roger Penske, Founder and Chairman of the Penske Corporation.

Solutions for Testing Wireless, IP, Fiber Optics, Analog, and TDM Networks

Retrieved on: 
Monday, January 22, 2024
Voice over IP, EVS, Digital, GPS, ATM, API, Switch, NVM Express, Land mobile radio system, HDL, GSM, PPP, GTP, Noise, IP, Communication, Wide area network, SONET, Wireless, ITU, APS, Drive, CAMA, PESQ, Google Maps, Computer network, CAS, Phonation, ISDN, CLI, FXO, Voice over LTE, SMS, Human, SS7, Automation, TDM, RAW, RFC, Human voice, Data-rate units, OC-48, IUP, 3GPP, POLQA, GPRS, Language, Solid-state drive, INAP, TCP, ATA, MAP, Frame Relay, Optical fiber, Analog, AMR, HTTP, Estrone, ISAC, Mobile phone

“GL Communications Inc. is a leading test and measurement equipment manufacturer for Wireless, IP, Fiber Optic, Analog and TDM networks.

Key Points: 
  • “GL Communications Inc. is a leading test and measurement equipment manufacturer for Wireless, IP, Fiber Optic, Analog and TDM networks.
  • GL also offers consulting services to design, implement, verify, and inspect communications systems including wireless, IP, satellite, fiber optic, digital, and microwave networks.
  • GL offers multi-functional Ethernet testers to test individual devices such as cables, switches, routers, as well as end-to-end Ethernet/IP networks.
  • The test tools operate at wirespeed (1/10/25/40/50/100 Gbps) and offer bit error rate testing, RFC 2544, ITU-T Y.1564 and RFC 6349 based TCP testing.

Bad Idea AI Announces Collaboration with Publishing CEO for New AI News Platform

Retrieved on: 
Friday, January 19, 2024
Journalism, Machine learning, Bad Idea, GTP, Natural language processing, Bad Ideas, News, Publishing, AI, Customer service

Lewes, DE, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Bad Idea AI , an emerging player in the crypto project space, has announced a collaboration with a national publishing CEO to launch a news platform driven by AI technology.

Key Points: 
  • Lewes, DE, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Bad Idea AI , an emerging player in the crypto project space, has announced a collaboration with a national publishing CEO to launch a news platform driven by AI technology.
  • Set for launch on January 23rd, the project, affectionately known as " Bad Ideas ," revolves around the Bad Idea AI ecosystem.
  • It brings together the cutting-edge technology of Bad Idea AI with the rich experience of the publishing CEO.
  • A unique aspect of the Bad Idea AI project is its holistic use of AI.

Zynga and Automobili Lamborghini S.p.A. Announce Multi-year Deal Making CSR Racing Official Partner of Lamborghini’s Squadra Corse Racing Team

Retrieved on: 
Wednesday, January 24, 2024
Motor Sports, Sports, Automotive, Technology, Licensing (Entertainment), Electronic Games, Mobile Entertainment, Entertainment, Apps, Applications, Software, Performance & Special Interest, Senior, IMSA, Le Mans, Multimedia, Partnership, Racing, Google Play, TTWO, CSR, Lamborghini Aventador, CSR3, App, CSR Racing, NaturalMotion, Take-Two Interactive, Love, Calendar, WEC, FIA, Inc., GTP, Video game

Over 30 Lamborghini cars have previously appeared in the CSR2 mobile game, and the complementary partnership adds content to both parties, putting the CSR2 brand on the cars, drivers, and teams of Lamborghini Squadra Corse while continuing to add Lamborghini cars to CSR2.

Key Points: 
  • Over 30 Lamborghini cars have previously appeared in the CSR2 mobile game, and the complementary partnership adds content to both parties, putting the CSR2 brand on the cars, drivers, and teams of Lamborghini Squadra Corse while continuing to add Lamborghini cars to CSR2.
  • Over 30 Lamborghini cars have previously appeared in the CSR2 mobile game, and the complementary partnership adds content to both parties, putting the CSR2 brand on the cars, drivers, and teams of Lamborghini Squadra Corse while continuing to add Lamborghini cars to CSR2.
  • (Photo: Business Wire)
    For the first time in the company’s history, Lamborghini will enter the FIA Hypercar and IMSA GTP class.
  • The Lamborghini Squadra Corse will enter 12 races globally across the FIA and IMSA championships in 2024.

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

Retrieved on: 
Wednesday, January 3, 2024
Switch II, Lung cancer, Neoplasm, IND, FDA, GTP, FNL, Cancer, Patient, Switch, UCSF, Pharmaceutical industry

BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity.

Key Points: 
  • BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity.
  • BBO-8520 drives substantial tumor growth inhibition in multiple preclinical models, even after emergence of resistance to sotorasib, an FDA approved (OFF) state inhibitor of KRASG12C.
  • “BBO-8520 is the most potent G12C inhibitor with an IND, and the only compound that directly binds and targets the ON state.
  • Enrollment of patients with KRASG12C mutant non-small cell lung cancer into the ONKORAS-101 trial is expected to begin in H1 of this year.